Novartis tender offer for MorphoSys commences
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
He takes over leadership of Cell & Gene from Jean-Christophe Hyvert, enabling Jean-Christophe to increase his focus on his role as President of the Biologics Division
Subscribe To Our Newsletter & Stay Updated